| developability assessment for lead compound | From discovery to eventually marketing, pharmaceutical companies would spend a huge sum of money for a new therapeutic drug development. One of the underlying reasons for this huge cost is the exceptionally high rate of failure observed in the development process. Approximately 90% of drug candidates failed during clinical trials because of unsatisfactory physical and chemical properties of drug molecules, intolerable toxicity and low efficacy. The direct transition of molecules selected during early discovery stage with suboptimal properties to late-stage development may require expensive and time-consuming formulation and development efforts. The failure rate of the therapeutic drug could be reduced by "developability" at an early stage. |